Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels
Author:
Affiliation:
1. AstraZeneca; Mölndal Sweden
2. Formerly AstraZeneca; Wilmington DE USA
3. Bristol-Myers Squibb; Princeton NJ USA
Funder
AstraZeneca
Publisher
Wiley
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12500/fullpdf
Reference14 articles.
1. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension;Landsberg;J Clin Hypertens (Greenwich),2013
2. Beneficial health effects of modest weight loss;Goldstein;Int J Obes Relat Metab Disord,1992
3. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD);Inzucchi;Diabetes Care,2012
4. Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus;Chen;Diabetes Obes Metab,2013
5. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes;Lambers Heerspink;Diabetes Obes Metab,2013
Cited by 41 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Antihypertensive effect of Dapagliflozin in Type II diabetic patients with Hypertension;Research Journal of Pharmacy and Technology;2024-02-20
2. Treatment Approaches and Challenges;Nanoscience Applications in Diabetes Treatment;2023-12-17
3. Perspectives in weight control in diabetes – SGLT2 inhibitors and GLP-1–glucagon dual agonism;Diabetes Research and Clinical Practice;2023-05
4. Effects of sodium-glucose cotransporter 2 inhibitors on renal risk factors in patients with abnormal glucose metabolism: a meta-analysis of randomized controlled trials;European Journal of Clinical Pharmacology;2023-04-25
5. Risk of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Treated with Dapagliflozin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials;Clinical Drug Investigation;2023-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3